PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE - VAN DIJK M.; RAB M.; VAN OIRSCHOT B.; BOS J.; DERICHS C.; RIJNEVELD A.; CNOSSEN M.; NUR E.; BIEMOND B.; BARTELS M.; JANS J.; VAN SOLINGE W.; et al. (HemaSphere, 2022)